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Rheumatoid arthritis is associated with reduced
adiposity but not with unfavorable major
cardiovascular risk factor profiles and enhanced
carotid atherosclerosis in black Africans from a
developing population: a cross-sectional study
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Abstract
Introduction: Rheumatoid arthritis (RA) is characterized by inflamed joint-derived cytokine-mediated high-grade
systemic inflammation that enhances cardiovascular metabolic risk and disease in developed populations. We
investigated the potential impact of RA on cardiovascular risk factors including systemic inflammation and
atherosclerosis, and their relationships in black Africans from a developing population.
Methods: We evaluated demographic features, adiposity indices, major traditional cardiovascular risk factors,
circulating C-reactive protein and interleukin-6 concentrations and ultrasound determined carotid intima-media
thickness (cIMT) in 274 black Africans; 115 had established RA. Data were analyzed in confounder-adjusted mixed
regression models.
Results: The body mass index and waist-height ratio were lower in RA compared to non-RA subjects (29.2 (6.6)
versus 33.7 (8.0), P < 0.0001 and 0.58 (0.09) versus 0.62 (0.1), P = 0.0003, respectively). Dyslipidemia was less
prevalent in patients with RA (odds ratio (OR) (95% confidence interval (CI) = 0.54 (0.30 to1.00)); this disparity was
no longer significant after further adjustment for reduced adiposity and chloroquine use. RA was also not
associated with hypertension, current smoking and diabetes. The number of major traditional risk factors did not
differ by RA status (1.1 (0.8) versus 1.2 (0.9), P = 0.7). Circulating C-reactive protein concentrations were similar and
serum interleukin-6 concentrations reduced in RA (7.2 (3.1) versus 6.7 (3.1) mg/l, P = 0.7 and 3.9 (1.9) versus 6.3 (1.9)
pg/ml, P < 0.0001, respectively). The cIMT was 0.700 (0.085) and 0.701 (0.111) mm in RA and non-RA subjects,
respectively (P = 0.7). RA disease activity and severity parameters were consistently unrelated to systemic
inflammation, despite the presence of clinically active disease in 82.6% of patients. In all participants, adiposity
indices, smoking and converting angiotensin inhibitor non-use were associated with increased systemic
inflammation, which related to more atherogenic lipid profiles, and circulating low density lipoprotein
concentrations were associated with cIMT (partial R = 0.153, P = 0.032); RA did not impact on these relationships
(interaction P ≥0.1).
Conclusions: Among black Africans, patients with established RA experience reduced overall and abdominal
adiposity but no enhanced major traditional risk factor and atherosclerosis burden. This study further suggests that
an absent interleukin-6 release by inflamed RA joints into the circulation may account for this unaltered
cardiovascular disease risk.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and
potentially destructive joint disorder that is complicated
by enhanced atherosclerosis and incident cardiovascular
event rates similar to diabetes [1-6], as well as cardiovas-
cular mortality [4,7].
In the general population, the bulk of cardiovascular
disease (CVD) is attributable to the traditional risk fac-
tors of hypertension, dyslipidemia, smoking and diabetes
[8,9]. In addition, cytokine-mediated systemic inflamma-
tion as generally estimated by circulating C-reactive pro-
tein concentrations (CRP), contributes to atherogenesis
[10-19]. Systemic inflammation originates mostly in
excess adiposity and smoking, and mediates CVD
through adverse effects on metabolic cardiovascular risk
factors as well as more direct effects at the endothelial
level [10-19].
RA is characterized by circulating CRP concentrations
that are typically increased several fold even when the
disease appears clinically controlled [20,21]. Although,
in RA, adiposity and smoking associate independently
with serum CRP concentrations [22], the inflammation
extent is mostly accounted for by circulating joint
derived cytokines, particularly interleukin-6 [20-22].
Several genetic polymorphisms were recently found
to be associated with CVD in RA [23-27]. Amongst the
modifiable cardiovascular risk factors, it is the chronic
high-grade systemic inflammatory state that is cur-
rently considered to best explain the excess CVD in
RA [20,21,28-31]. Congruent with this paradigm, sys-
temic inflammation is associated with metabolic risk
factors, including insulin resistance and decreased high
density lipoprotein (HDL) cholesterol concentrations in
RA [20,21,32,33]. A recent meta-analysis of traditional
cardiovascular risk factors in RA indeed confirmed the
presence of lower HDL cholesterol concentrations and
an enhanced diabetes frequency [34]. Importantly in
the present context also, high-grade inflammation in
RA is complicated by a reduced lean mass and particu-
larly muscle mass together with increased body fat
accumulation, a condition most often termed rheuma-
toid cachexia [35,36]. Adiposity associates with meta-
bolic risk factors in RA [36-38]. With regard to more
recently identified cardiovascular risk factor pathways,
circulating interleukin-6 concentrations are indepen-
dently associated with endothelial activation [21] that
decreases upon suppression of interleukin-6 production
in RA [39].
Besides systemic inflammation in RA, antirheumatic
agents can modify cardiovascular risk factors. Although
short term glucocorticoid therapy in patients with mark-
edly active RA can enhance insulin sensitivity [20],
chronic use of this intervention associates with insulin
resistance [40], atherosclerosis [41] and cardiovascular
event rates [42]. Chloroquine therapy induces favorable
lipid profiles [43,44] and lowered diabetes risk [45] and
leflunomide use hypertension [46] and dyslipidemia [47].
As applies to the general population, available data on
atherogenesis in RA were generally obtained in subjects
that belong to developed populations, whereas 80% of
CVD now occurs in low income or developing countries
[38,48-52]. In this regard, we recently documented con-
sistent disparities in individual cardiovascular risk factor
profiles including more marked overall adiposity, an
increased prevalence of hypertension and less frequent
alcohol consumption in patients with RA from develop-
ing groups of black African descent compared to their
white counterparts from a developed population, as well
as risk factor-atherosclerosis relationships amongst both
groups [38,51,52]. Non-RA black African subjects
experience not only a very large prevalence of obesity
[53] and hypertension [54,55], but also a strikingly large
systemic inflammation burden [56-58], whereas serum
C-reactive protein concentrations are not increased in
black Africans compared to white patients with RA [52].
Further, cumulative inflammation as estimated by the
number of deformed joints, is independently associated
with decreased overall and abdominal obesity in African
black but not white women with RA [38]. In the present
study, we examined the potential impact of RA on car-
diovascular risk factors, including systemic inflamma-
tion, carotid atherosclerosis and their relationships
amongst 274 African blacks.
Materials and methods
Study participants
The present investigation was conducted according to the
principles outlined in the Helsinki declaration. The Com-
mittee for Research on Human Subjects of the University
of Witwatersrand approved the protocols applied in non-
RA and RA subjects (approval numbers: M02-04-72 and
renewed as M07-04-69 in non-RA subjects and M06-07-
33 in RA subjects). Participants gave informed, written
consent. The present study design has previously been
described [38,50-52,56,59-61]. Briefly, 115 African black
patients who met the 1988 American College of Rheuma-
tology criteria for RA [62] were enrolled at the Charlotte
Maxeke Johannesburg Academic Hospital. All invited
patients agreed to participate. Only two RA subjects used
prednisone and, hence, to avoid confounding of the data
analysis by this intervention, the respective participants
were excluded. All patients used disease modifying agents
for rheumatic disease (DMARDs) at the time of the
study. Age- and sex-matched non-RA subjects were parti-
cipants in a population study on cardiovascular risk and
disease that is also conducted in Johannesburg [56,59-61].
This investigation comprises randomly recruited nuclear
families of black African descent with siblings older than
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16 years. Of the 159 non-RA participants, 124 had CRP
measurements and 92 carotid ultrasound evaluations; the
other recorded variables did not differ in non-RA subjects
with and without CRP and carotid ultrasound assess-
ments. Data were missing in fewer than 5% of any of the
other recorded cardiovascular risk factors in the study
participants.
Baseline characteristics
We recorded demographic features, life style factors
comprising alcohol use (at least one unit per month)
and exercise (at least once per month) that included
time spent in walking, for example, to reach public
transportation, and cardiovascular and non-steroidal
anti-inflammatory drug (NSAID) use. Height, weight
and waist and hip circumference were measured using
standard approaches. Body mass index (BMI) cut-off
points of <20, 20 to 24.9, 25 to 29.9 and >29.9 kg/m2
were employed to identify underweight, normal weight,
overweight and obese status, respectively. Abdominal
obesity indices included waist circumference and waist-
height ratio whereas fat distribution was estimated by
the waist-hip ratio [38]. In patients with RA, we addi-
tionally recorded disease duration, the Clinical Disease
Activity Index (CDAI) [63], the number of deformed
joints (cumulative inflammation or disease severity),
rheumatoid factor status and the use of traditional or
synthetic DMARDs. Patients with RA had no access to
biological DMARD therapy at the time of the study
[38,50-52].
Conventional cardiovascular risk factors
Hypertension was defined as an average systolic blood
pressure ≥140 or/and diastolic blood pressure ≥90
mmHg or/and current use of antihypertensive medica-
tions. Uncontrolled and untreated hypertension were
diagnosed in patients with a systolic blood pressure
≥140 or/and diastolic blood pressure ≥90 mmHg who
used and did not use antihypertensive agents, respec-
tively. Standard laboratory blood tests of renal and liver
function, hematological parameters, lipids and glucose
were performed. Dyslipidemia was diagnosed when the
atherogenic index, that is, the cholesterol-HDL choles-
terol ratio was more than four and proatherogenic
non-HDL cholesterol concentrations were calculated by
subtracting HDL cholesterol from total cholesterol con-
centrations [38,44,50-52]. We documented smoking
habits. Diabetes was identified as the use of glucose low-
ering agents or a fasting plasma glucose ≥7 mmol/l. The
overall major conventional cardiovascular risk factor
burden was estimated by the number and proportion of
patients with one or more of such risk factors that com-
prised hypertension, dyslipidemia, current smoking
status and diabetes, as well as the Framingham 10-year
risk prediction scores for coronary heart disease (myo-
cardial infarction or coronary death) [8] and general
CVD (myocardial infarction, coronary death, coronary
insufficiency, angina, ischemic stroke, hemorrhagic
stroke, transient ischemic attack, peripheral vascular dis-
ease or heart failure) [9].
Systemic inflammation
Serum CRP and interleukin-6 comprised the evaluated
laboratory inflammatory markers in the present investi-
gation. CRP concentrations were determined using
immunoturbidimetric methods. In non-RA subjects,
this was done on the AU analyzer (Olympus, Essex,
UK), the lower detection limit was 0.05 mg/l and the
inter- and intra-assay coefficients of variation were 1.3
and 0.4%, respectively; in RA patients it was performed
on the DxC/LX analyzer (Beckman Coulter, Inc., Brea,
CA, USA), the lower detection limit was 1 mg/l and
the inter- and intra-assay were 2.5 and 5.0%, respec-
tively. In the general population, a CRP concentration
>1 mg/l reportedly predicts increased incident CVD
[16,19]. Seventy-four blood samples from subjects who
did not participate in the present study were tested on
both the AU and DxL/LX systems and the Spearman
correlation coefficient between the obtained CRP
values was 0.994. Interleukin-6 concentrations were
measured using a solid-phase sandwich enzyme-linked
immunosorbant assay (ELISA) (Quantikine®HS, R&D
Systems, Inc., Minneapolis, MN, USA). The lower
detection limit ranged from 0.016 to 0.110 pg/ml and
inter- and intra-assay coefficients of variation were 7.8
and 7.4%, respectively.
Carotid artery atherosclerosis
Carotid artery intima-media thickness (cIMT) measure-
ments were made using a linear array 7.5 MHz probe
attached to a high resolution B-mode ultrasound
machine (SonoCalc IMT, Sonosite, Inc., Bothell, WA,
USA) in both RA and non-RA subjects, as recently
described [38,51,52]. This equipment involves the appli-
cation of a unique semi-automated border detection
program that was previously documented to provide
highly reproducible intra- and inter-rater results in
other as well as our settings [38,51,52,61,64]. Carotid
artery plaque is currently identified in our RA patients
[38,51,52] but not in non-RA subjects and, hence,
results on plaque are not shown in the present report.
Data analysis
Dichotomous variables are expressed as proportions or
percentages and continuous variables as mean (SD).
Non-normally distributed characteristics were logarith-
mically transformed prior to statistical analysis and for
these variables geometric means (SD) are given. The
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selection of confounders in multivariable regression
models was both data driven and based on biological
plausibility.
Disparities in demographic features between RA and
non-RA subjects were compared using the Student’s
t-test and univariate logistic regression analysis as
appropriate. Relationships of RA with baseline recorded
characteristics, major cardiovascular risk factors,
systemic inflammation and atherosclerosis were first
investigated in multivariable logistic and continuous
regression models as appropriate with consistent adjust-
ment for demographic characteristics since age differed
numerically by RA status. The associations between RA
and cardiovascular risk factors, systemic inflammation
and atherosclerosis status were then re-assessed in mod-
els that included additional potential confounders or/
and mediators.
In all participants, the relation of circulating CRP and
interleukin-6 concentrations with potential determinants
of systemic inflammation and metabolic cardiovascular
risk factors were investigated in demographic character-
istic as well as in multiple confounder adjusted models.
The impact of RA on these relationships was deter-
mined by employing interaction terms [38,51,52].
Finally, in patients with RA, the associations of clinical
disease activity and severity variables with systemic
inflammation were investigated in demographic and
multiple confounder adjusted models.
Statistical computations were made using the GB
Stat™ program (Dynamic Microsystems, Inc., Silver-
spring, MD, USA).
Results
Baseline characteristics in African black subjects with and
without RA
Table 1 gives the baseline characteristics in the study
participants. The proportion of women was numerically
larger by 3.4% amongst those with compared to those
without RA. Alcohol was consumed only by non-RA
subjects (17.6%), who also exercised more than their
RA counterparts. The BMI was substantially lower in
RA compared to non-RA subjects (difference in mean
= 4.5 kg/m2). In age and sex adjusted analysis, black
Africans with RA had more frequently a normal BMI
(odds ratio (OR) (95% confidence interval (CI)) = 3.42
(1.69 to 6.95)) and were less often obese (OR (95% CI)
= 0.35 (0.21 to 0.59)) than those without RA. Abdominal
obesity measures (waist and waist-height ratio) were lar-
ger in non-RA subjects whereas RA was not associated
with an altered fat distribution (waist-hip ratio). Hyper-
tension was treated in 72.1% and 61.5% (OR (95% CI) =
1.76 (0.93 to 3.33)) of RA and non-RA cases, respectively.
Antihypertensive agents were more frequently employed
(OR (95% CI) = 1.87 (1.12 to 3.11)) and the mean
number of antihypertensives prescribed was twice as
large in subjects with compared to those without RA; this
was mostly due to a more regular use of angiotensin con-
verting enzyme inhibitors (OR (95% CI) = 10.00 (4.80 to
20.85)) and calcium channel blockers (OR (95% CI) =
4.01 (1.66 to 9.69)). Amongst treated hypertensive partici-
pants, 58.5% of non-RA subjects compared to 67.7% of
RA patients had uncontrolled hypertension (systolic
blood pressure ≥140 or/and diastolic blood pressure ≥90
mm Hg) (OR (95% CI) = 1.49 (0.71 to 3.14)).
In patients with RA, the mean disease duration was
12.5 years, 76.5% tested rheumatoid factor positive,
17.4% experienced clinical remission and 53% moderate
or high disease activity. Methotrexate and chloroquine
comprised the most frequently prescribed DMARDs and
the mean number of DMARDs used was 2.4.
Conventional cardiovascular risk factor profiles in African
black subjects with and without RA
Table 2 shows the conventional cardiovascular risk fac-
tor profiles in black Africans with and without RA. In
age- and sex-adjusted analysis (Model 1 in Table 2), RA
was associated with less frequent dyslipidemia (OR (95%
CI) = 0.54 (0.30 to 1.00)) and consistently more favor-
able individual lipid parameters. Subjects with RA had a
similar frequency of ever smoking but had discontinued
smoking more often than their non-RA counterparts.
Amongst smokers, the mean number (SD) of cigarettes
smoked per day was low at 4.1 (2.3). The overall major
conventional cardiovascular risk factor burden as esti-
mated by the number of major risk factors, the presence
of at least one major risk factor and the 10-year risks
for coronary heart disease and cardiovascular disease
were similar in subjects with and without RA.
Besides disparities in adiposity measures between RA
and non-RA subjects (Table 1), other factors that could
have confounded or mediated our findings in Model 1
(Table 2) included chloroquine [43-45] and leflunomide
use [46,47]. Thus, amongst patients with RA and in age,
sex, cardiovascular drug, obesity measure and lifestyle
factor adjusted analysis, potentially relevant relationships
(P < 0.2) were found between chloroquine and lefluno-
mide use and the cholesterol-HDL cholesterol ratio
(partial R = -0.153, P = 0.13 and partial R = 0.158, P =
0.12, respectively). Leflunomide use also potentially
impacted on systolic blood pressure but this constituted
an inverse relationship (partial R = -0.177, P = 0.08)
thereby arguing against an adverse effect of leflunomide
on blood pressure amongst black Africans with RA. None
of the other RA characteristics (Table 1) were found to be
potential confounders or mediators in the associations
between RA and cardiovascular risk factors (P > 0.2).
The mediating or confounding effects of disparities of
adiposity indices between RA and non-RA subjects,
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Table 1 Baseline characteristics in African black subjects with and without rheumatoid arthritis
Rheumatoid arthritis
Characteristic Present (n = 115) Absent (n = 159) P-valuea
Demographics
Age, years 55.7 (10.3) 56.5 (10.9) 0.5
Female (%) 89.6 86.2 0.45
Lifestyle factors
Alcohol use (%) 0 17.6 -
Units per week, numberb 0 0.27 (1.08) -
Exercise (%) 41.7 42.8 1.0
Hours per week, numberb 0.1 (1.0) 1.7 (2.4) 0.0004
Anthropometric measures
Body mass index 29.2 (6.6) 33.7 (8.0) <0.0001
<20 kg/m2 (%) 5.4 2.5 0.2
20 to 24.9 kg/m2 (%) 25.2 8.8 0.0004
25 to 29.9 kg/m2 (%) 25.2 23.3 0.8
>29.9 kg/m2 (%) 44.1 64.8 0.0001
Waist circumference, cm 93.1 (13.3) 97.5 (15.0) 0.01
Waist/height 0.58 (0.09) 0.62 (0.1) 0.0003
Hip circumference, cm 110 (18) 116 (15) 0.002
Waist/hipb 0.85 (1.14) 0.84 (1.13) 0.4
Cardiovascular drugs
Antihypertensive agents
Use (%) 53.9 40.2 0.02
Number 1.0 (1.1) 0.5 (0.7) <0.0001
>1 agent (%) 36.5 8.8 <0.0001
Diuretic (%) 38.3 39.0 1.0
Angiotensin converting enzyme inhibitor (%) 40.8 6.9 <0.0001
Calcium channel blocker (%) 16.5 5.0 0.002
Beta blocker (%) 3.5 0 -
Angiotensin receptor blocker (%) 0.9 0 -
Glucose lowering agents
Oral glucose lowering agent (%) 13.9 10.1 0.3
Insulin (%) 0.9 2.5 0.3
Statin (%) 19.1 0 -
Nonsteroidal antiinflammatory agent (%) 6.1 4.4 0.6
Rheumatoid arthritis characteristics
Disease duration, years 12.5 (8.8)
Clinical Disease Activity Indexb [58] 8.3 (2.6)
<2.8 or remission (%) 17.4
2.7 to 10 or mild disease activity (%) 29.6
11 to 22 or moderate disease activity (%) 40.0
>22 or high disease activity (%) 13.0
Deformed joints, numberb 6.2 (2.7)










Results are expressed as mean (SD) or proportions/percentages. aExcept for associations between rheumatoid arthritis status and demographic characteristics,
adjusted for age and gender; bnon-normally distributed variables for which geometric mean (SD) is given.
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leflunomide and chloroquine use and systemic inflamma-
tion on the associations between RA and cardiovascular
risk factors (Model 1 in Table 2) are shown in models 2
to 5. In Model 2, additional adjustment for anthropo-
metric measures consistently attenuated the inverse
associations between RA and lipid variables. In Model 3,
further adjustment for leflunomide use strengthened the
respective associations thereby confirming an adverse
effect of leflunomide on serum lipid concentrations. In
keeping with the above reported negative borderline rela-
tionship between leflunomide use and systolic blood pres-
sure, the association between RA and hypertension was
also strengthened and, in fact, significant. In Model 4,
additional adjustment for chloroquine use resulted in a
complete lack of association between RA and lipid para-
meters. In Model 5, further adjustment for serum CRP
and interleukin-6 concentrations did not materially alter
the results in Model 4. The same applied when lifestyle
factors were adjusted for (data not shown).
In a separate model, the number of antihypertensives
used (Table 1) remained higher in RA compared to non-
RA subjects independent of demographic characteristics,
life style factors, obesity measures, systemic inflammation
and leflunomide use; amongst patients with RA, none of
the disease characteristics were related to the number of
antihypertensives used (data not shown).
Systemic inflammation in African black subjects with and
without RA
In age and sex adjusted analysis, circulating interleukin-6
concentrations were strongly associated with circulating
CRP concentrations (partial R = 0.396, P < 0.0001) and
the presence of RA did not impact on this relationship
(interaction P > 0.1)
Table 2 further gives serum CRP and interleukin-6
concentrations in the study subjects. Serum CRP
concentrations did not differ and the serum interleukin-6
concentrations were lower in RA compared to non-RA
subjects (P = 0.7 and P < 0.0001, respectively, in age and
sex adjusted analysis) (Model 1 in Table 2). Adjustment
for obesity measures did not materially alter these results
(Model 2 in Table 2). Also, further adjustment for alcohol
use, cigarettes smoked per day and the use of angiotensin
converting enzyme inhibitors that were additional poten-
tial confounders in the present context (see analyses
below), did not materially alter the relationship between
RA and systemic inflammation (data not shown).
The lack of impact of RA on CRP concentrations and
reduced interleukin-6 concentrations in patients with
RA is unexpected. Therefore, we further measured CRP
and interleukin-6 concentrations in 122 African whites
with RA that formed part of an investigation that was
previously reported by us [52]. We used the same assay
as in all subjects and the one employed in non-RA sub-
jects in the present study upon quantifying CRP and
interleukin-6 concentrations (see methods), respectively.
In African white patients with RA, the geometric mean
(SD) CRP and interleukin-6 concentrations were 4.3
(3.7) mg/l and 3.6 (2.2) pg/ml, respectively. CRP concen-
trations were higher in black compared to white patients
(P = 0.002 and 0.03 before and after adjustment for con-
founders (see Table 3)) and those of interleukin-6 were
similar in both groups (P = 0.4 and 0.4 before and after
adjustment for confounders).
Carotid artery atherosclerosis in African black subjects
with and without RA
The carotid artery atherosclerosis burden in African black
subjects with and without RA is also shown in Table 2.
In age and sex adjusted analysis, the cIMT was similar in
both groups (P = 0.7) (Model 1 in Table 2). Further
adjustment for anthropometric measures, leflunomide
Table 3 Associations of potential determinants of systemic inflammation with CRP and interleukin-6 concentrations in
all participants
C-reactive proteina Interleukin-6a








Partial R P Partial R P Partial R P Partial R P
Body mass index 0.240 0.0003 -0.005 0.9 0.227 0.0002 0.148 0.02
Waist circumference 0.318 <0.0001 0.173 0.005
Waist/height 0.302 <0.0001 0.188 0.005 0.182 0.004 -0.001 1.0
Waist/hipa 0.163 0.01 0.054 0.39
Number of cigarettes/daya 0.017 0.8 0.034 0.6 0.128 0.04 0.130 0.04
Alcohol use 0.065 0.3 0.048 0.5 0.162 0.008 0.098 0.1
ACE inhibitor use 0.051 0.4 0.056 0.4 -0.144 0.019 -0.127 0.045
Model 0.350 0.331
Significant associations are shown in bold. aNon-normally distributed variables that were logarithmically transformed. Except for alcohol use (only in participants
without rheumatoid arthritis), none of the relationships differed in black Africans with versus those without rheumatoid arthritis (interaction P = 0.1 to 0.9). CRP,
C-reactive protein.
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and chloroquine use and systemic inflammation did not
alter these results (models 2 to 5 in Table 2).
Factors associated with systemic inflammation in African
black subjects with and without RA
Table 3 gives the significant associations between the
potential determinants of systemic inflammation that
were recorded in subjects with and without RA (charac-
teristics shown in Table 1) and serum CRP and interleu-
kin-6 concentrations. In age- and sex-adjusted analysis,
each anthropometric measure was associated with CRP
concentrations and overall and abdominal obesity mea-
sures as well as the number of cigarettes smoked, alcohol
use and angiotensin converting enzyme inhibitor therapy
were associated with interleukin-6 concentrations. In
additional models in which these characteristics (except
for waist circumference and waist-hip ratio that were
omitted because of co-linearity) were entered together as
independent variables, the waist-height ratio remained
associated with serum CRP concentrations and the BMI,
number of cigarettes smoked per day and angiotensin
converting enzyme inhibitor therapy were independently
associated with interleukin-6 concentrations. None of the
relationships between potential determinants of systemic
inflammation and serum CRP and interleukin-6 concen-
trations differed in black African subjects with compared
to those without RA (interaction P = 0.1 to 0.9).
Table 4 shows the analyses of the associations
between recorded clinical disease activity and disease
severity (deformed joint count) measures and serum
CRP and interleukin-6 concentrations in subjects with
RA. Both in age and sex adjusted models as well as in
models that included additional adjustment for potential
confounders (Table 3), there were no significant rela-
tionships; the same was true when the respective asso-
ciations reassessed in subgroups with no or mild disease
activity (Table 5) and moderate and high disease activity
(Table 7), respectively. In fact, in those with more
marked disease activity, a borderline inverse relationship
between the swollen joint count and interleukin-6 con-
centrations was noted. These results were also unex-
pected. Hence, to ensure that the lack of association
between CRP concentrations and clinical disease activity
and severity measures is specific to African black
patients with RA in our setting, we also assessed the
respective relationships in African whites with estab-
lished RA that formed part of our previously reported
investigation [52]. Indeed, in these patients, upon adjust-
ment for demographic characteristics, the log swollen
joint count (partial R = 0.536, P < 0.0001), log tender
joint count (partial R = 0.429, P < 0.0001), log doctor
disease activity (partial R = 0.628, P < 0.0001), patient
disease activity (partial R = 0.464, P < 0.0001), log CDAI
(partial R = 0.580, P < 0.0001), CDAI >2.7 (partial R =
0.481, P < 0.0001) and log deformed joint count (partial
R = 0.254, P = 0.005) were each strongly associated with
log CRP concentrations. Upon further adjustment for
additional potential confounders (Table 3), these rela-
tionships remained equally strong (partial R = 0.531,
0.425, 0.614, 0.460, 0.516, 0.462 and 0.284 for log swol-
len and log tender joint count, log doctor and patient
disease activity, log CDAI and CDAI >2.7 and log
deformed joint count (P < 0.003 for each), respectively).
Table 7 gives the significant associations of serum CRP
and interleukin-6 concentrations with the recorded cardi-
ovascular risk factors (Table 2) in African black subjects
with and without RA. In age and sex adjusted models,
both inflammatory markers were related to metabolic risk
that comprised lipid variables. None of the associations
between systemic inflammation and cardiovascular risk
factors differed in African black subjects with compared
to those without RA (interaction P = 0.4 to 0.9).
Relationships between cardiovascular risk factors and
carotid artery atherosclerosis in African subjects with and
without RA
In age-, sex- and statin therapy-adjusted models, serum
low-density lipoprotein (LDL) cholesterol concentrations
Table 4 Relationships of disease activity and severity with systemic inflammation in all 115 African RA patients
C-reactive proteina Interleukin-6a
Disease activity variable Age and sex adjusted model Multivariable adjusted modelb Age and sex adjusted model Multivariable
adjusted modelb
Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.081 0.4 0.102 0.3 -0.136 0.2 -0.101 0.3
Tender jointsa 0.005 1.0 0.009 0.9 -0.029 0.8 -0.012 0.9
Doctor disease activitya 0.061 0.5 0.057 0.6 0.077 0.4 0.126 0.2
Patient disease activity -0.053 0.6 0.082 0.4 0.101 0.3 0.090 0.4
CDAIa 0.065 0.5 0.049 0.6 0.083 0.4 0.031 0.8
CDAI >2.7 0.069 0.5 0.088 0.4 0.129 0.2 0.163 0.1
Deformed jointsa 0.040 0.7 0.103 0.3 -0.027 0.8 -0.016 0.9
aNon-normally distributed variables that were logarithmically transformed; badditionally adjusted for potential confounders of body mass index, waist:height ratio
and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease Activity Index.
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were associated with cIMT (partial R = 0.153, P = 0.032).
Further adjustment for other traditional risk factors com-
prising hypertension, diabetes and smoking did not mate-
rially alter these associations (R = 0.135, P = 0.06). The
other recorded cardiovascular risk factors (Table 2) were
not associated with cIMT and the relationships between
cardiovascular risk factors and cIMT were consistently
similar in black African subjects with compared to those
without RA (interaction P > 0.2).
Discussion
Among African black subjects from a developing popu-
lation, patients with RA experienced markedly reduced
adiposity compared to their non-RA counterparts. RA
was not independently associated with hypertension,
dyslipidemia, smoking and diabetes and the overall
major traditional risk factor burden was similar in RA
compared to non-RA subjects. Serum CRP concentra-
tions were not increased in RA and further unrelated to
disease activity and severity, a finding that was specific
to African black patients with RA. The carotid artery
atherosclerosis extent did not differ by RA status. To
our knowledge, this is the first study that evaluated the
association of RA with cardiovascular risk factors and
atherosclerosis in African black persons.
In the present study, non-RA subjects experienced an
apparently large systemic inflammation burden with
mean circulating CRP and interleukin-6 concentrations
of 6.7 mg/l and 6.3 pg/ml, respectively. Of likely rele-
vance in the present context, the pro-inflammatory cyto-
kine interleukin-6 IL-6-174 G/G genotype was found
36.5 (95% CI = 8.8 to 159.1) times more frequently in
African compared to white Americans [65]. The most
striking finding in the current investigation was the
Table 5 Relationships of disease activity and severity with systemic inflammation in non- or mildly active RA.
C-reactive proteina Interleukin-6a








Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.082 0.6 0.063 0.7 -0.189 0.2 -0.147 0.3
Tender jointsa -0.067 0.6 -0.100 0.5 -0.173 0.2 -0.168 0.3
Doctor disease activitya 0.044 0.8 0.017 0.9 -0.126 0.4 -0.027 0.9
Patient disease activity -0.148 0.3 -0.139 0.3 0.070 0.6 0.011 0.9
CDAIa -0.034 0.8 -0.060 0.7 -0.143 0.3 -0.116 0.4
Deformed jointsa 0.071 0.6 0.119 0.4 -0.081 0.6 0.013 0.9
Fifty-four patients had no or mild disease activity (CDAI = 0 to 10). aNon-normally distributed variables that were logarithmically transformed; badditionally
adjusted for potential confounders of body mass index, waist:height ratio and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease
Activity Index.
Table 7 Associations of systemic inflammation with
cardiovascular risk factors in RA and non-RA African
subjects
Cardiovascular risk factor C-reactive proteina Interleukin-6a
Partial R P Partial R P
HDL chola -0.247 0.0002 -0.109 0.08
Chol/HDL chol 0.208 0.002 0.104 0.10
Triglycerides/HDL chola 0.170 0.01 0.147 0.02
LDL chol/HDL chola 0.202 0.002 0.038 0.5
Relationships were assessed in age and sex adjusted models. Significant
associations are shown in bold. HDL, high density lipoprotein; chol, cholesterol;
LDL, low density lipoprotein. None of the relationships differed in black Africans
versus those without rheumatoid arthritis (interaction P = 0.4 to 0.9).
Table 6 Relationships of disease activity and severity with systemic inflammation in moderately or highly active RA
C-reactive proteina Interleukin-6a








Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.025 0.9 0.113 0.4 -0.260 0.07 -0.246 0.1
Tender jointsa 0.028 0.8 0.014 0.9 -0.131 0.4 -0.120 0.4
Doctor disease activitya 0.100 0.5 0.084 0.6 0.212 0.2 0.232 0.1
Patient disease activity -0.092 0.5 -0.066 0.7 0.222 0.1 0.225 0.2
CDAIa 0.066 0.6 0.111 0.5 0.125 0.4 0.147 0.3
Deformed jointsa 0.041 0.8 0.028 0.8 0.012 0.9 -0.050 0.7
Sixty-one patients had moderate or high disease activity (CDAI > 10). aNon-normally distributed variables that were logarithmically transformed; badditionally
adjusted for potential confounders of body mass index, waist:height ratio and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease
Activity Index.
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absence of increased systemic inflammation in RA com-
pared to non-RA subjects despite the presence of clini-
cally active disease [63] in >80% of the patients. This is
in sharp contrast to the RA associated six- to seven-fold
increase in both CRP and interleukin-6 concentrations
in a study on mostly white patients with RA, as pre-
viously reported by us [21]. In addition, there was an
overall lack of impact of RA on the relationships of cir-
culating interleukin-6 and CRP concentrations with
their potential determinants and metabolic risk factors.
The concentrations of circulating interleukin-6 that con-
stitute the major determinant of hepatic CRP produc-
tion [12,17] were higher in non-RA compared to RA
black Africans even after adjusting for confounders.
However, the full impact of disparities in potential con-
founders including adiposity measures, smoking, alcohol
consumption and angiotensin converting enzyme inhibi-
tor use [16,66-68] on the association of RA status with
circulating interleukin-6 concentrations may not have
been accounted for in multivariable models, particularly
given the cross-sectional design of our study.
Our findings have important implications. First, they
suggest that interleukin-6 produced in inflamed joints is
not released into the circulation in black Africans with
established RA. As well, the very low prevalence of extra-
articular manifestations among black Africans with RA
[52,69] supports the presence of an inflammatory process
that is mostly restricted to the joints. Since race specific
therapeutic responses to interleukin-6 blockade with toci-
lizumab were not observed in randomized controlled
trials that included black patients, interleukin-6 should be
equally important in the pathogenesis of RA induced
synovitis in black compared to other subjects [70].
Second, based on reported consistent results that origi-
nate in patients with RA from developed populations, a
lack of adverse impact of RA on systemic inflammation
would be expected to translate in unaltered cardiovascular
risk factor profiles and disease [20,21,32,33,71,72]. Indeed,
among African black subjects, RA was not related to
adverse metabolic risk and atherosclerosis. Furthermore,
whereas in patients with RA from developed populations,
the associations of traditional cardiovascular risk factors
with CVD are weakened due to the substantial contribu-
tion of systemic inflammation to cardiovascular mortality
[31], in the present study, black Africans with RA experi-
enced similar cardiovascular risk factor-atherosclerosis
associations compared to their non-RA counterparts.
Third, our findings could explain the apparent dispari-
ties in RA-adiposity relationships among our patients
and those that participated in previously reported stu-
dies [35-37,73,74]. Thus, patients with RA from devel-
oped populations sustain reduced lean body mass and
increased adiposity that is mediated mainly by systemic
inflammation and results in an overall unaltered or
increased BMI and waist circumference, together with a
more central fat distribution that enhances cardiovascular
metabolic risk [35-37,73,74]. Accordingly, this condition
has also been termed ‘rheumatoid cachectic obesity’ and
‘hypercytokinaemic cachexia’ [35]. In the present study,
RA in black persons was associated with reduced overall
and abdominal obesity indices and not with an altered fat
distribution as estimated by waist-hip ratio. Waist
circumference is determined by abdominal fat and hip
circumference by lean mass and subcutaneous fat [75,76].
The waist and hip circumference were reduced to a simi-
lar extent in RA compared to non-RA subjects in this
study. Reduced adiposity indices partially explained more
favorable lipid profiles in RA in mixed regression models
and, hence, may protect against CVD. Although systemic
inflammation was not increased in African black patients
with RA, their cumulative joint inflammation was distinc-
tively large with a mean joint deformity count of 9.7. The
joint deformity count is inversely related to BMI, waist
and waist-height but not waist-hip ratio in African black
women with RA [38] and the same relationships were
found in the present investigation (data not shown).
Reported findings together with our results therefore
indicate that high-grade systemic and joint restricted
inflammation may have disparate effects on adiposity and
its distribution in RA.
Last, C-reactive protein concentrations should not be
relied upon when determining the need for DMARD
intensification in African black patients with RA.
Chloroquine, a long standing treatment in rheumatic
diseases, can reduce hepatic cholesterol synthesis and
increase LDL receptor numbers on fibroblasts and
enhances insulin secretion and sensitivity [43-45]. We
found that the associations of RA with a range of serum
lipid concentrations and their ratios, including the tri-
glycerides-HDL cholesterol ratio that is a marker of
insulin resistance [77], were attenuated and no longer
significant once chloroquine use was accounted for. Stu-
dies aimed at determining the true independent impact
of RA on cardiovascular risk factor profiles should con-
sider confounding by RA treatment.
Despite a low smoking prevalence and the small num-
ber of cigarettes consumed daily, the 10-year risk for
CVD was substantial at approximately 10% in black
Africans. These data are reminiscent of an earlier health
transition stage that characterizes developing popula-
tions [49,50].
As previously reported in developed populations, RA
was not associated with an augmented prevalence of
hypertension in the present investigation [34]. Further,
high frequencies of untreated and uncontrolled hyper-
tension were documented earlier in RA [46] and, in
black Africans, these also did not differ by RA status.
Notably, however, despite similar blood pressure values
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to those in non-RA subjects, patients with RA employed
more frequent and twice as many antihypertensive
agents, a disparity that remained unexplained in multi-
variable analysis. Whether and how RA could influence
hypertension responsiveness to antihypertensive therapy
deserves to be determined in longitudinal studies.
The present study has further limitations. Carotid
artery plaques are more strongly associated with coron-
ary heart disease and its risk factors than cIMT that
relates more closely to stroke and its determinants [38].
Nevertheless, both cIMT and plaque predict future car-
diovascular event rates in RA and non-RA subjects irre-
spective of ethnicity [78-81]. Serum LDL concentrations
were independently associated with cIMT that therefore
would be expected to reflect atherosclerosis and coron-
ary heart disease risk in black Africans. As applies to
most studies on CVD, many relationships were evalu-
ated. Our main findings each originated in confounder-
adjusted multivariable models.
Conclusions
RA associates with markedly reduced overall and
abdominal adiposity in black Africans. However, in con-
founder adjusted analysis, RA did not impact on major
traditional cardiovascular risk factor profiles, athero-
sclerosis extent and their relationships in this popula-
tion. An absence of interleukin-6 release by inflamed
RA joints into the circulation may account for this unal-
tered cardiovascular risk.
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